Market Overview

LabConnect Elects Eric Richman as Chairman of the Board

Share:

LabConnect,
LLC
, a leading global provider of central laboratory and support
services for biopharmaceutical, medical device and contract research
organizations, today announced that its board of directors has elected
Eric I. Richman as chairman of the board.

"I'm delighted Eric has accepted the role of chairman of LabConnect,"
said Eric
Hayashi
, president and CEO. "He brings with him an insider's
knowledge of the needs of our biopharmaceutical clients, and I look
forward to a close relationship with him as we write the next chapter of
LabConnect's story together."

Richman will succeed Alain Chetrit, LabConnect cofounder and chairman,
who will now serve as chairman emeritus. During Chetrit's tenure as
board chairman, LabConnect experienced sustained compound annual growth
of more than 30 percent.

"I am proud to have had the opportunity to create and contribute to a
thriving organization that betters lives, and I'm confident that Eric
Richman will help guide the company on a similar trajectory," said
Chetrit.

"Alain, together with Eric and his team, has done a terrific job
building a growth engine with a passion for listening and responding to
the unique needs of small to midsized biopharmaceutical clients. I'm
grateful for Alain's service over the last 16 years," added Eric
Richman. "I'm excited to take part in transformational innovation in our
industry."

Richman has more than 25 years of experience as a life science executive
as a founding team member of MedImmune where he was responsible for the
launch of MedImmune's first commercial product, CytoGam®, and
as president and CEO of PharmAthene. His board experience at
biopharmaceutical companies includes ADMA Biologics (NASDAQ:ADMA),
NovelStem, Inc., Lev Pharmaceuticals and Tyrogenex.

About LabConnect, LLC
Founded in 2002, LabConnect provides
global central laboratory and client-inspired support services including
routine and specialized laboratory testing, kit building, sample
management, data management, biorepository and scientific support
services for biopharmaceutical and CRO clients. LabConnect's unique
combination of state-of-the-art technology, world-class laboratories,
easy access to major and emerging markets and extensive specialized
testing expertise means that drug development companies can rely on one
provider for their central laboratory and preclinical through Phase IV
clinical development needs. Learn more at labconnectllc.com
or connect with LabConnect on LinkedIn.

View Comments and Join the Discussion!